GTCM
XENE icon

Gyon Technologies Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Gyon Technologies Capital Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-36,279
Closed -$1.13M – 594
2021
Q4 		$1.13M Buy
36,279
+23,445
+183% +$701K 0.21% 139
2021
Q3 		$196K Buy
+12,834
New +$223K 0.05% 357

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Gyon Technologies Capital Management's XENE Position: Q1 2022 in Review

Gyon Technologies Capital Management sold out of Xenon Pharmaceuticals (XENE) in Q1 2022, closing a stake of 36,279 shares — an estimated $1.13M sold.

Gyon Technologies Capital Management first reported a position in XENE in Q3 2021 and held it in 2 quarters. The position peaked at $1.13M in Q4 2021. 133 funds tracked by Wall St. Rank hold XENE as of Q1 2022.

  • Gyon Technologies Capital Management reported no remaining Xenon Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 36,279 Xenon Pharmaceuticals shares in Q1 2022, an estimated $1.13M.
  • Gyon Technologies Capital Management first reported a position in Xenon Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • Gyon Technologies Capital Management's Xenon Pharmaceuticals position peaked at $1.13M in Q4 2021.
  • 133 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2022.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2022, filed 12 May 2022.